Once touted as a potential powerhouse treatment for a variety of inflammatory conditions, Galapagos’ JAK inhibitor Jyseleca ...

Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

A total of 209 patients received upadacitinib at a dose of 15 mg, 107 received upadacitinib at a dose of 7.5 mg, and 112 received placebo; 70% of the patients had new-onset giant-cell arteritis ...

Here we report the design of an open-label, randomized, phase 3 study (NCT06619236) to investigate Rina-S vs IC chemotherapy in pts with PROC. Methods: This phase 3 study will enroll ~530 pts with ...

Methods: The multiregional, randomized, double-blind, phase 3 HARMONi-3 trial (NCT05899608) will compare the efficacy and tolerability of ivonescimab plus chemotherapy with pembrolizumab plus ...

In this phase 3, double-blind, randomized, placebo-controlled trial, we enrolled participants with myasthenia gravis who had anti–acetylcholine receptor antibodies or anti–muscle-specific ...

Viking Therapeutics advances its dual GLP-1/GIP obesity drug into Phase 3 trials, entering a $100 billion weight loss market. Applied Digital's $7 billion CoreWeave partnership transforms it into an ...